TG Therapeutics’ (TGTX) “Buy” Rating Reiterated at HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $49.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 93.83% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. B. Riley increased their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Trading Up 0.8 %

Shares of NASDAQ:TGTX traded up $0.20 during trading on Wednesday, reaching $25.28. 1,970,327 shares of the company traded hands, compared to its average volume of 3,624,379. The firm has a market capitalization of $3.91 billion, a price-to-earnings ratio of 109.91 and a beta of 2.21. TG Therapeutics has a 52-week low of $6.46 and a 52-week high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The business’s fifty day moving average is $21.73 and its 200-day moving average is $18.15.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm’s revenue for the quarter was up 357.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.34) earnings per share. As a group, analysts forecast that TG Therapeutics will post 0.13 EPS for the current year.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently modified their holdings of the business. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter valued at $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the second quarter valued at $35,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of TG Therapeutics during the first quarter valued at $58,000. nVerses Capital LLC boosted its position in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,500 shares during the last quarter. Finally, Quarry LP boosted its position in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 503 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.